Project Grant F31CA298725
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $619,764 to the University of Wisconsin - Madison to develop new combination immunotherapy strategies for treating triple-negative breast cancer (TNBC). The key objectives are to: 1) increase the tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor (P-aPDL1) by triggering local thrombus formation in TNBC tumors, and 2) modulate the immunosuppressive...
- This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
- This $214,583 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Tulane University will fund research to evaluate the role of the extracellular matrix in triple-negative breast cancer (TNBC) progression and treatment response, with a focus on African American patient populations. The research aims to provide insights on key extracellular matrix proteins that regulate TNBC tumorigenesis, metastasis, and response to therapy, using 3D in...
- The National Cancer Institute awarded a $442,343 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Dartmouth-Hitchcock Clinic to investigate therapeutic targeting of the tumor microenvironment in triple negative breast cancer patients at high risk of relapse. The key objectives are to: 1) disrupt cancer cell mitochondrial bioenergetics and invasion/metastasis, 2) disrupt the "pre-metastatic niche" that supports metastatic tumor cell colonization and...
- This Project Grant award of $545,983.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at Northwestern University to study the role of the protein PlexinB2 in the metastasis of triple-negative breast cancer (TNBC). The goal is to identify molecular regulators of the interactions between circulating tumor cells (CTCs) and the host immune system, with the objective of developing strategies to inhibit TNBC metastasis. The project will run from...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,129 to The Johns Hopkins University to conduct research on leveraging a DDX3 inhibitor, RK-33, in combination with immunotherapy to treat triple-negative breast cancer (TNBC). The goal is to alter the tumor's metabolic environment in a way that enhances the effectiveness of immunotherapy, potentially leading to an "abscopal effect" where the treatment induces regression...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $399,829 to the University of North Carolina at Chapel Hill to investigate the impact of the bacteria Fusobacterium nucleatum on breast cancer progression and treatment. The key objectives are to characterize how F. nucleatum alters the tumor microenvironment and immune response, and examine if targeting the bacterial infection can improve the efficacy of chemotherapy. The...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) to the University of Pittsburgh provides $165,486.00 to investigate how the intracellular protein MALT1 promotes immunosuppression in the tumor immune microenvironment of triple-negative breast cancer (TNBC). The award aims to analyze MALT1 regulation of the TNBC tumor immune microenvironment by characterizing MALT1 protease-dependent secretion of immunosuppressive cytokines from TNBC cells. This...
- The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...
- This $403,485 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of novel platinum-based therapeutics that can effectively induce high levels of reactive oxygen species (ROS) to treat triple-negative breast cancer (TNBC). The research, conducted by The Methodist Hospital Research Institute in Texas, aims to create new drug candidates that can rapidly eradicate TNBC cells and suppress tumor growth, particularly in cases...
NEUTROPHIL-DRIVEN PRO-RECURRENT NICHE FORMATION IN MAMMARY ADIPOSE TISSUE - PROJECT SUMMARY RECURRENCE REMAINS A SIGNIFICANT CHALLENGE FOR TRIPLE NEGATIVE BREAST CANCER (TNBC) PATIENTS DESPITE TREATMENT WITH SURGERY, CHEMOTHERAPY, AND RADIOTHERAPY (RT). ALTHOUGH IRRADIATION OF THE RESECTED TUMOR BED DECREASES RECURRENCE IN MOST PATIENTS, PATIENTS WITH CHRONIC LYMPHOPENIA AND A HIGH NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) FOLLOWING RT EXPERIENCE RELAPSE AT HIGH RATES. THE MECHANISMS UNDERLYING THIS ASSOCIATION OF HIGH NLR WITH RECURRENCE ARE POORLY UNDERSTOOD. HOWEVER, A GROWING BODY OF LITERATURE SHOWS THAT IRRADIATION OF MAMMARY ADIPOSE TISSUE INITIATES AN INNATE IMMUNE CELL-DRIVEN PROGRAM THAT FACILITATES TUMOR CELL RESEEDING. ADDITIONALLY, PRELIMINARY EVIDENCE SUGGESTS THAT IRRADIATION PROMOTES RECURRENCE VIA NEUTROPHIL-MEDIATED VASCULAR REMODELING AND SENESCENCE. THEREFORE, THE CENTRAL HYPOTHESIS OF THIS PROPOSAL IS THAT NEUTROPHILS FACILITATE FORMATION OF A PRO-RECURRENT NICHE IN IRRADIATED MAMMARY ADIPOSE TISSUE THROUGH RELEASE OF PRO-INFLAMMATORY PROTEINS AND IN- DUCTION OF VASCULAR REMODELING WHEN PRIMED BY SENESCENT CELLS. THE RATIONALE FOR THE PROPOSED RESEARCH IS THAT UNDERSTANDING THE IMPACT OF POST-THERAPY IMMUNE CELL INFILTRATION ON TUMOR CELL RESEEDING AND VASCULAR REMODEL- ING WILL IDENTIFY CANDIDATES FOR TARGETED THERAPIES. THE CENTRAL HYPOTHESIS WILL BE TESTED BY PURSUING TWO SPECIFIC AIMS: 1) DETERMINE NEUTROPHIL PHENOTYPES AND FUNCTIONS ASSOCIATED WITH TUMOR CELL RESEEDING IN IRRADIATED ADI- POSE TISSUE; AND 2) IDENTIFY THE EFFECT OF NEUTROPHIL ACTIVATION ON PRO-ANGIOGENIC SIGNALING AND VASCULAR REMODEL- ING. IN AIM 1, I WILL USE A LYMPHOPENIC MOUSE MODEL TO REPRESENT AT-RISK PATIENT POPULATIONS AND ESTABLISH HOW NEUTROPHIL INFILTRATION TO IRRADIATED MAMMARY ADIPOSE TISSUE FACILITATES RECURRENCE. TO CONFIRM THAT NEUTROPHILS ARE NECESSARY AND SUFFICIENT FOR TUMOR CELL RECRUITMENT INTO ADIPOSE TISSUE, I WILL DEVELOP A NEUTROPHIL-DEPLETED MOUSE MODEL. IN AIM 2, I WILL DETERMINE THE INFLUENCE OF THE SENESCENT ENDOTHELIAL CELL SECRETOME ON NEUTROPHIL ACTIVA- TION, USING A WELL-CHARACTERIZED MICROFLUIDIC MODEL OF THE MAMMARY VASCULATURE TO ANALYZE HOW THIS ACTIVATION PROMOTES NF-KB AND PRO-ANGIOGENIC SIGNALING IN ENDOTHELIAL CELLS. I WILL THEN EVALUATE THE IMPACT OF NEUTROPHIL PROTEINS ON NF-KB SIGNALING AND VASCULAR REMODELING AS WELL AS ON TUMOR CELL RECRUITMENT TO IRRADIATED ADIPOSE TISSUE IN VIVO. THESE STUDIES WILL IDENTIFY MECHANISMS OF NEUTROPHIL-MEDIATED VASCULAR REMODELING AND TUMOR CELL RESEEDING AFTER RT, PROVIDING TWO POTENTIAL POINTS OF INTERVENTION TO PREVENT RECURRENCE IN PATIENTS WITH TNBC.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $49.5k | 7/15/25 | ||
| Not listed | $0 | 7/15/25 | ||
| Not listed | $49.5k | 7/15/25 |